Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Issuance of common stock for services Stock Issued During Period, Value, Issued for Services Title of 12(b) Security Title of 12(b) Security Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Prepaid product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Number of RSUs (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Customer [Axis] Customer [Axis] Segment Reporting [Abstract] Common stock, $0.0001 par value per share; 500,000,000 shares authorized; 249,147,061 and 244,351,501 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Additional Details of Leases Schedule Of Additional Details Of Leases [Table Text Block] The tabular disclosure of additional details of the leases. Accrued compensation and benefits Employee-related Liabilities, Current Term Loan 2022 A, B, C Term Loan 2022 A, B, C [Member] Term Loan 2022 A, B, C Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash, Cash Equivalent, and Short-Term Investment [Text Block] Restatement Determination Date Restatement Determination Date Short-term investments Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures XPHOZAH Product, XPHOZAH [Member] Product, XPHOZAH Term Loans 2022 A, B, C, D, E, and H Term Loans 2022 A, B, C, D, E, and H [Member] Term Loans 2022 A, B, C, D, E, and H Amendment Flag Amendment Flag Current liabilities Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Inventory, non-current Inventory, non-current Inventory, Noncurrent Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Number of defendants Loss Contingency, Number of Defendants Loss Contingencies [Table] Loss Contingencies [Table] Leases [Abstract] Leases [Abstract] Copay Assistance and Returns Contract With Customer, Copay and Returns [Member] Contract With Customer, Copay and Returns Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Non-cash royalty revenue related to the sale of future royalties Non-Cash Royalty Related To Sale Of Future Royalties Non-Cash Royalty Related To Sale Of Future Royalties PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Assets Assets, Fair Value Disclosure [Abstract] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Unested restricted stock units, beginning balance (in shares) Unvested restricted stock units, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Shares used in computing net loss per share - basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Noncurrent Inventory Schedule of Inventory, Noncurrent [Table Text Block] Contingencies [Line Items] Loss Contingencies [Line Items] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Additional details Lessee, Operating Lease, Description [Abstract] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Beginning balance Ending balance Contract With Customer, Gross To Net Sales Accruals Contract With Customer, Gross To Net Sales Accruals Deferred revenue Increase (Decrease) in Deferred Revenue Adjustments to principal value Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net [Abstract] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Lease costs Lease, Cost [Abstract] Entity Address, City or Town Entity Address, City or Town Kyowa Kirin Kyowa Kirin Co. Ltd [Member] Represents the information pertaining to Kyowa Kirin Co., Ltd. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Advance Royalties [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Title and Position [Domain] Title and Position [Domain] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Product sales, net Product [Member] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Proceeds from ESPP Proceeds from Stock Plans Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Licensing revenue License License [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Caremark, LLC Caremark, LLC [Member] Caremark, LLC Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Three Lessee, Operating Lease, Liability, To Be Paid, After Year Three General and administrative General And Administrative Expense, Adjusted General And Administrative Expense, Adjusted Schedule of Information Regarding Operating Segment Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Total cash, cash equivalents and investments, Gross Unrealized Losses Cash Cash Equivalents And Investments Gross Unrealized Losses Cash, cash equivalents and investments gross unrealized losses. Less Segment Reporting, Reconciliation [Abstract] Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Total long-term debt Long-Term Debt Schedule of Undiscounted Cash Payment Obligations for Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Supplemental disclosure of non-cash activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Document Period End Date Document Period End Date Changes in operating assets and liabilities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Term loan face amount Debt Instrument, Face Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two STOCKHOLDERS’ EQUITY Equity [Text Block] Security Exchange Name Security Exchange Name Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Product supply delivered Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Cash and cash equivalents Cash and Cash Equivalent [Abstract] Current portion of operating lease liability Current portion of lease liabilities Less: Current portion of operating lease liability Operating Lease, Liability, Current Issuance of common stock for services (in shares) Stock Issued During Period, Shares, Issued for Services NET LOSS PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification IBSRELA Product, IBSRELA [Member] Product, IBSRELA Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Purchase price (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share Represents the purchase price per share of shares issued to employees under the plan. Unrealized losses on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Total principal Long-Term Debt, Gross Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalent, and Investment [Table Text Block] Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cardinal Health, Inc. Cardinal Health, Inc [Member] Cardinal Health, Inc Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Shares used in computing net loss per share - diluted (in shares) Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Commercial paper Commercial Paper [Member] U.S. treasury securities US Treasury Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Imputed interest expenses Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue from Contract with Customer [Abstract] 2022 Term Loan Term Loan 2022 [Member] Term Loan 2022 Cash paid for operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total undiscounted operating lease payments Lessee, Operating Lease, Liability, to be Paid Unvested restricted stock units, beginning balance (in dollars per share) Unvested restricted stock units, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Plan Name [Domain] Plan Name [Domain] Prepaid commercial manufacturing Prepaid Commercial Manufacturing, Current Prepaid Commercial Manufacturing, Current Outstanding balance, beginning (in dollars per share) Outstanding balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use assets Right-of-use assets Operating Lease, Right-of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Gross To Net Adjustments of Revenue Schedule Of Gross To Net Sales Adjustments Of Revenue [Table Text Block] Schedule Of Gross To Net Sales Adjustments Of Revenue Schedule of Computation of Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] SEGMENT REPORTING Segment Reporting [Text Block] Expiration Date Trading Arrangement Expiration Date Schedule of Revenue Disaggregation of Revenue [Table Text Block] Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Prepaid product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Threshold percentage of net sales for tiered royalties Threshold Percentage of Sales For Tiered Royalties Represents the threshold percentage of net sales for tiered royalties. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercise Price Award Exercise Price Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Segment Reporting [Line Items] Segment Reporting [Line Items] Unrecognized Compensation Expense (in thousands) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Proceeds from maturities and redemptions of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Stock-based Compensation [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] BORROWING Debt Disclosure [Text Block] Unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] Fosun Pharma Shanghai Fosun Pharmaceutical Industrial Development [Member] Represents Shanghai Fosun Pharmaceutical Industrial Development. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Reclassify amounts to be recognized in the next 12 months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Total costs and operating expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Knight License Agreement Development Commercialization Distribution In Canada [Member] Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement. Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Other income, net Nonoperating Income (Expense) Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accreted value of final fee Debt Instrument, Fee Amount Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total operating lease liabilities Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Outstanding balance, beginning (in shares) Outstanding balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] ESPP ESPP shares issuable Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Selling, General and Administrative Expense COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of segments Number of Operating Segments RSU grants Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] AZ Termination Agreement AstraZeneca Termination Agreement [Member] AstraZeneca Termination Agreement Entity Central Index Key Entity Central Index Key Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other, net Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Income Statement [Abstract] Stockholders’ equity Equity, Attributable to Parent [Abstract] Reportable Segment Reportable Segment [Member] Reportable Segment Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Costs and operating expenses Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Number of Shares (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Floating per annum rate (as percent) Debt Instrument, Basis Spread on Variable Rate City Area Code City Area Code Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Deferred Royalty Obligation [Roll Forward] Deferred Royalty Obligation [Roll Forward] Deferred Royalty Obligation All Individuals All Individuals [Member] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Name Forgone Recovery, Individual Name Average Remaining Vesting Period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Line Items] Statement [Line Items] Total assets Assets Undiscounted cash payment obligations Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Product supply revenue Product Supply Revenue [Member] Product Supply Revenue Interest expense Interest Expense, Nonoperating Schedule of Stock-Based Compensation Expense Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Commission on sale of stock per agreement (as percent) Stock Issuance Cost, Commission, Percent Stock Issuance Cost, Commission, Percent Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax EQUITY INCENTIVE PLANS​ Share-Based Payment Arrangement [Text Block] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock in at-the-market offering (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Term F Loan Term Loan 2022 F [Member] Term Loan 2022 F Total cash, cash equivalents and investments Investments and Cash Stock-based compensation Share-Based Payment Arrangement, Expense Investment in continuous unrealized loss position for more than one year Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Issuance of common stock upon exercise of options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Final fee due upon maturity, acceleration, prepayment, or termination (as percent) Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage AstraZeneca Astrazeneca [Member] Represents information pertaining to AstraZeneca. Accumulated Deficit Retained Earnings [Member] Operating lease liability, net of current portion Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Money market funds Money market funds Money Market Funds [Member] DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES Asset Retirement Obligation Disclosure [Text Block] Forfeited or cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Forfeited or cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Corporate bonds Corporate Debt Securities [Member] Net loss per share of common stock - diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Litigation Case [Domain] Litigation Case [Domain] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Research and development Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenues Revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Debt Instrument, Redemption, Period Three Debt Instrument, Redemption, Period Three [Member] Fosun Pharma License Agreement Development Commercialization Distribution In China [Member] Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement. (in thousands) Non-current Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward] Change In Contract With Customer Liability, Noncurrent, Rollforward Financial Instruments [Domain] Financial Instruments [Domain] Term A Loan Term Loan 2022 A [Member] Term Loan 2022 A INVENTORY Inventory Disclosure [Text Block] Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Kyowa Kirin License Agreement Development Commercialization Distribution In Japan [Member] Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement. Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Purchases of investments Payments to Acquire Short-Term Investments Prepaid commercial manufacturing, non-current Prepaid Commercial Manufacturing, Noncurrent Prepaid Commercial Manufacturing, Noncurrent REVENUE Revenue from Contract with Customer [Text Block] Other reconciliation items Segment Reporting, Other Reconciling Item, Amount Segment Reporting, Other Reconciling Item, Amount Forfeited or cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Proceeds from issuance of common stock under equity incentive plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Inventory Increase (Decrease) in Inventories Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Segment Reporting [Table] Segment Reporting [Table] Issuance of common stock for services Stock Issued Title and Position [Axis] Title and Position [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Royalty and commercialization milestone payments remitted to HCR Increase (Decrease) To Deferred Royalty Obligation, Royalty And Commercialization Milestone Payments Remitted Increase (Decrease) To Deferred Royalty Obligation, Royalty And Commercialization Milestone Payments Remitted Cash Cash [Member] Schedule of Lease Costs Lease, Cost [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Yankee bonds Debt Security, Government, Non-US [Member] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Selling Selling Expense, Adjusted Selling Expense, Adjusted Reported as Inventory, Gross [Abstract] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted-Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Provisions Contract With Customer, Gross To Net Sales, Provisions Contract With Customer, Gross To Net Sales, Provisions Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished goods Inventory, Finished Goods, Gross Non-cash interest expense Amortization of Debt Discount (Premium) Allowance for credit loss on available for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Short-term investments Debt Securities, Available-for-Sale, Current Equity Components [Axis] Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Products and Services [Domain] Product and Service [Domain] Cash paid for income taxes Income Tax Paid, after Refund Received Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Healthcare royalty partners IV, L.P HealthCare Royalty Partners IV, L.P [Member] HealthCare Royalty Partners IV, L.P Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Rebates, Wholesaler and GPO Fees Contract With Customer, Rebates, Wholesaler And GPO Fees [Member] Contract With Customer, Rebates, Wholesaler And GPO Fees Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Cencora, Inc. Cencora, Inc. [Member] Cencora, Inc. Other assets Other Assets, Noncurrent Document Type Document Type Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Deferred revenue, non-current Beginning balance Ending balance Contract with Customer, Liability, Noncurrent Work in process Inventory, Work in Process, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name NATURE OF OPERATIONS Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Knight Knight Therapeutics Inc [Member] Represents information pertaining to Knight Therapeutics Inc. Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 14) Commitments and Contingencies Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] BioRidge Pharma, LLC BioRidge Pharma, LLC [Member] BioRidge Pharma, LLC Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Schedule of Fair Value of Financial Assets Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total Inventory, Net Award Type [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Remainder of 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] U.S. government-sponsored agency bonds US Government Agencies Debt Securities [Member] Collaboration and Licensing Agreements Collaboration and Licensing Agreements n/a Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] PEO Name PEO Name Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Payment Contract with Customer, Liability Loan agreement, covenant, sum of net product revenue and unrestricted cash as percentage of outstanding loan balance, calculation period (in months) Loan Agreement, Covenant, Sum Of Net Product Revenue And Unrestricted Cash As Percentage Of Outstanding Loan Balance, Calculation Period Loan Agreement, Covenant, Sum Of Net Product Revenue And Unrestricted Cash As Percentage Of Outstanding Loan Balance, Calculation Period Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Repayment of Loan Agreement, including fees Repayments of Secured Debt Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Prepayment premium (as percent) Debt Instrument, Prepayment Premium Fee, Percentage Debt Instrument, Prepayment Premium Fee, Percentage (in thousands) Current Change In Contract With Customer Liability, Current, Rollforward [Roll Forward] Change In Contract With Customer Liability, Current, Rollforward Product Concentration Risk Product Concentration Risk [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Deferred royalty obligation related to the sale of future royalties Deferred royalty obligation balance as of January 1, Deferred royalty obligation balance as of June 30, Deferred Royalty Obligation, Noncurrent Deferred Royalty Obligation, Noncurrent Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Discounts and Chargebacks Contract With Customer, Discounts And Chargebacks [Member] Contract With Customer, Discounts And Chargebacks Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Term C Loan Term Loan 2022 C [Member] Term Loan 2022 C Reclassify amounts to be recognized in the next 12 months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Customer [Domain] Customer [Domain] Schedule of Current Inventory Schedule of Inventory, Current [Table Text Block] LEASES Lessee, Operating Leases [Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net loss per share of common stock - basic (in dollars per share) Earnings Per Share, Basic Product supply delivered Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Raw materials Inventory, Raw Materials, Gross Maximum potential payment per agreement Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Deferred revenue Beginning balance Ending balance Contract with Customer, Liability, Current Total current assets Assets, Current Insider Trading Arrangements [Line Items] Right-of-use assets and lease liabilities Assets and Liabilities, Lessee [Abstract] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Unrealized losses on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Proceeds from Loan Agreement, net of costs Proceeds from Issuance of Secured Debt Common Stock Common Stock [Member] Long-term debt Loans Payable, Noncurrent Fair Value Assets Debt Securities, Available-for-Sale Open Market Sales Agreement 2025, At The Market Offering Open Market Sales Agreement 2025, At The Market Offering [Member] Open Market Sales Agreement 2025, At The Market Offering Operating lease expense Operating Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Product sales, net as a percentage of total revenues Concentration risk (as percent) Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Loan Agreement Loans Payable [Member] Credits/payments Contract With Customer, Gross To Credits Or Deductions Issued Contract With Customer, Gross To Credits Or Deductions Issued Equity Awards Adjustments Equity Awards Adjustments [Member] COLLABORATION AND LICENSING AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Term H Loan Term Loan 2022 H [Member] Term Loan 2022 H Stock option grants Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Total cash, cash equivalents and investments, Gross Unrealized Gains Cash Cash Equivalents And Investments Gross Unrealized Gains Cash, cash equivalents and investments gross unrealized gains. Research and development Research And Development Expense, Adjusted Research And Development Expense, Adjusted Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Effective interest rate Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Prepaid commercial manufacturing Prepaid Commercial Manufacturing Prepaid Commercial Manufacturing Prepaid commercial manufacturing Increase (Decrease) In Prepaid Commercial Manufacturing Expense Increase (Decrease) In Prepaid Commercial Manufacturing Expense Total future payment obligation Long-Term Debt, Excluding Interest Payments Long-Term Debt, Excluding Interest Payments Less: Current portion of long-term debt Loans Payable, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Term B Loan Term Loan 2022 B [Member] Term Loan 2022 B Non-cash interest expense related to the sale of future royalties Increase (Decrease) To Deferred Royalty Obligation, Non-Cash Interest Expense Related To Sale Of Future Royalties Increase (Decrease) To Deferred Royalty Obligation, Non-Cash Interest Expense Related To Sale Of Future Royalties Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Forfeited or cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Non-cash royalty revenue related to the sale of future royalties Non-Cash Royalty Related To Sale of Future Royalties [Member] Non-Cash Royalty Related To Sale of Future Royalties Adjustment to Compensation: Adjustment to Compensation [Axis] Term Loan 2022 F And G Term Loan 2022 F And G [Member] Term Loan 2022 F And G Total cash, cash equivalents and investments, Amortized Cost Investments And Cash, Amortized Cost Investments And Cash, Amortized Cost Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] McKesson Corporation McKesson Corporation [Member] McKesson Corporation Go v. Raab Go Versus Raab [Member] Go Versus Raab Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total Assets, Fair Value Disclosure Gross product revenue Revenue, Product and Service Benchmark [Member] Name Measure Name Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of Financial Information Related to HCR Agreement Schedule Of Deferred Royalty Obligation [Table Text Block] Schedule Of Deferred Royalty Obligation Debt Instrument [Line Items] Debt Instrument [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Director Director [Member] Gross-to-net sales accruals and reserves Contract With Customer, Gross To Net Sales Accrual [Roll Forward] Contract With Customer, Gross To Net Sales Accrual Name Trading Arrangement, Individual Name Cash and cash equivalents Fair Value Cash and Cash Equivalent Term G Loan Term Loan 2022 G [Member] Term Loan 2022 G Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Company Selected Measure Amount Company Selected Measure Amount Term D Loan Term Loan 2022 D [Member] Term Loan 2022 D Depreciation and amortization expense Depreciation, Depletion and Amortization Inventory Inventory Inventory, Gross Entity Address, Address Line Two Entity Address, Address Line Two Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Current assets Assets, Current [Abstract] Weighted-average remaining term (in years) Operating Lease, Weighted Average Remaining Lease Term Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Provision for income taxes Income Tax Expense (Benefit) Loan agreement covenant, sum of net product revenue and unrestricted cash as percentage of outstanding loan balance, minimum Loan Agreement, Covenant, Sum of Net Product Revenue and Unrestricted Cash As Percentage Of Outstanding Loan Balance, Minimum Loan Agreement, Covenant, Sum Of Net Product Revenue And Unrestricted Cash As Percentage Of Outstanding Loan Balance, Minimum Non-cash interest expense related to the sale of future royalties Non-Cash Interest Expense Related To Sale Of Royalties Non-Cash Interest Expense Related To Sale Of Royalties Customer Customer Concentration Risk [Member] Cost of sales Cost of Product and Service Sold Award Timing Method Award Timing Method [Text Block] Other cost of revenue Product and Service, Other [Member] Net increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Numerator Net Income (Loss) Attributable to Parent [Abstract] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Term E Loan Term Loan 2022 E [Member] Term Loan 2022 E Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Ardelyx, Inc. Stockholder Derivative Litigation Ardelyx, Inc. Stockholder Derivative Litigation [Member] Ardelyx, Inc. Stockholder Derivative Litigation Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Deferred Revenue Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Number of lawsuits Loss Contingency, New Claims Filed, Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Maximum aggregate offering price Maximum Aggregate Offering Price Amount of maximum aggregate offering price. Revenues Revenues [Abstract] U.S. treasury securities US Treasury Notes Securities [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]